At Travere Therapeutics, our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.
Volume:52 Week High:52 Week Low:
Data Provided by Refinitiv. Minimum 15 minutes delayed.
SAN DIEGO , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to review the Company’s key pipeline programs. The event will feature presentations from external experts
Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021 SAN DIEGO , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies In Rare for Life Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on November 19 SAN DIEGO , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Retrophin Inc.